₩8,340.00 ($6.21)

-140.00 (-1.65%)

Weekly Expected Move ±14.4%

₩5935 ₩7137 ₩8340 ₩9543 ₩10745

KSC · Healthcare · Drug Manufacturers - Specialty & Generic · Tech Score Neutral · Power 54 · ₩195.6B mcap · 22M float · 23.72% daily turnover

Revenue

$191.8B +9.1% ▲

5Y CAGR: +7.6%

Gross Profit

$78.2B +6.6% ▲

5Y CAGR: +6.1%

Operating Income

$3.3B +1724.0% ▲

5Y CAGR: +1.6%

Net Income

$2.5B +537.7% ▲

5Y CAGR: +2.8%

EPS (Diluted)

$96.28 +529.6% ▲

5Y CAGR: +3.8%

EBITDA

$7.6B +92.3% ▲

5Y CAGR: +0.6%

View Full Income Statement

Line Item	FY2021	FY2022	FY2023	FY2024	FY2025
Revenue	$139.8B	$162.7B	$180.8B	$175.7B	$191.8B
YoY Growth	+5.1%	+16.4%	+11.1%	-2.8%	+9.1%
Cost of Revenue	$83.5B	$93.9B	$105.5B	$102.4B	$113.6B
Gross Profit	$56.3B	$68.8B	$75.2B	$73.4B	$78.2B
Gross Margin	40.3%	42.3%	41.6%	41.7%	40.8%
R&D Expenses	$8.1B	$8.4B	$12.0B	$15.3B	$0
SG&A Expenses	$22.9B	$28.2B	$31.1B	$30.9B	$29.9B
Operating Expenses	$57.9B	$60.9B	$68.3B	$73.2B	$74.9B
Operating Income	-$812M	$8.0B	$6.9B	$181M	$3.3B
Operating Margin	-0.6%	4.9%	3.8%	0.1%	1.7%
Interest Expense	$713M	$1.2B	$1.9B	$2.0B	$1.9B
Income Before Tax	-$4.0B	$5.7B	$8.0B	-$1.7B	$2.3B
Tax Expense	-$848M	$5.8B	$1.9B	-$1.2B	-$209M
Net Income	-$3.2B	-$165M	$6.1B	-$575M	$2.5B
Net Margin	-2.3%	-0.1%	3.4%	-0.3%	1.3%
EPS (Diluted)	$-113.82	$-5.92	$225.81	$-22.41	$96.28
EBITDA	$273M	$10.0B	$13.2B	$3.9B	$7.6B
Shares Outstanding	28M	28M	27M	26M	26M

Line Item	FY2024 Q3	FY2024 Q4	FY2025 Q1	FY2025 Q2	FY2025 Q3	FY2025 Q4	FY2026 Q1	FY2026 Q2
Revenue	$46.2B	$42.9B	$43.1B	$48.4B	$51.6B	$48.7B	$46.5B	$55.6B
Cost of Revenue	$26.8B	$26.0B	$25.4B	$27.5B	$31.1B	$29.6B	$27.1B	$42.1B
Gross Profit	$19.5B	$16.9B	$17.7B	$20.9B	$20.5B	$19.1B	$19.4B	$13.5B
Gross Margin	42.1%	39.3%	41.1%	43.2%	39.8%	39.2%	41.7%	24.3%
R&D Expenses	$5.8B	$4.1B	$4.9B	$4.4B	$4.3B	$4.7B	$4.1B	$3.3B
SG&A Expenses	$7.4B	$7.7B	$13.0B	$8.3B	$13.0B	$7.6B	$6.1B	$8.9B
Operating Expenses	$19.9B	$18.9B	$18.1B	$19.8B	$17.6B	$19.3B	$16.8B	$12.6B
Operating Income	-$408M	-$2.0B	-$415M	$1.1B	$2.9B	-$235M	$2.5B	$910M
Operating Margin	-0.9%	-4.7%	-1.0%	2.2%	5.6%	-0.5%	5.4%	1.6%
Interest Expense	$487M	$511M	$506M	$337M	$454M	$446M	$474M	$463M
Income Before Tax	-$592M	-$2.9B	-$1.1B	$996M	$2.9B	-$538M	$2.1B	$852M
Tax Expense	-$105M	-$1.4B	-$109M	$40M	$399M	-$678M	$1.6B	-$360M
Net Income	-$487M	-$1.5B	-$985M	$956M	$2.5B	$268M	$420M	$1.2B
Net Margin	-1.1%	-3.4%	-2.3%	2.0%	4.9%	0.6%	0.9%	2.2%
EPS (Diluted)	$-19.00	$-57.63	$-37.70	$37.00	$97.35	$10.26	$16.03	$39.20
EBITDA	$569M	-$1.4B	$379M	$2.1B	$4.5B	$1.1B	$3.7B	$2.2B
Shares Outstanding	26M	26M	26M	26M	26M	26M	26M	31M

004310.KS KSC